Sublicense Agreement. A counterpart of the Sublicense Agreement executed by Seller;
Sublicense Agreement. SPE shall execute and deliver to Philips this Agreement and SPE shall have complied with all obligations to be complied with by SPE on or prior to the Closing Date under this Agreement on or prior to the Closing Date.
Sublicense Agreement. Licensor represents and warrants that it has no knowledge or belief, direct or indirect, that either the Inventors or the Licensor has any plan or intention to terminate the Sublicense Agreement and agrees to immediately notify Licensee in the event that it becomes aware of any such plan or intention. Licensor further agrees to take all reasonable steps to prevent termination of the Sublicense Agreement. Licensor acknowledges that if either such party does terminate the Sublicense Agreement during the term of this Agreement then Licensor will be subject to the Penalty Payment, as set forth in Section 6.3 of this Agreement.
Sublicense Agreement. In the event that the Acrux License Assignment Consent has not been obtained as of the Closing, the Seller shall grant to the Acquiror an exclusive sublicense under the Licensed Intellectual Property (as defined in the Acrux License) pursuant to, and upon the terms and subject to the conditions set forth in, the Sublicense Agreement, effective as of the Closing.
Sublicense Agreement. In accordance with Section 2.5(a), Roche shall have the right to [*] by Roche to Prothena under this Agreement.
Sublicense Agreement. Service Provider shall Sublicense the Software solely through a written Sublicense Agreement substantially in the form of the Alliance Partner License Agreement to be provided by PeopleSoft after the Effective Date ______; PROVIDED, HOWEVER, that in no instance shall Service Provider execute and enter into any Sublicense Agreement unless and until PeopleSoft has given its prior written consent to the final draft of such proposed Sublicense Agreement. In the event that Service Provider enters into any Sublicense Agreement in a form not expressly consented to by PeopleSoft pursuant to the terms of this subsection, such Sublicense Agreement shall be void AB INITIO.
Sublicense Agreement. (a) Full corporate name of sublicensee:
(b) Applicable country:
(c) Applicable indications in the Field:
(d) Standard of sublicensee’s performance (e.g. best efforts, commercially reasonable efforts, etc.):
(e) Term of sublicense agreement:
(f) Summary of termination provision:
Sublicense Agreement. The Sublicense Agreement between SmartGate, L.C. and RadioMetrix, a copy of which is attached as Exhibit "D" is in good standing and is enforceable. SmartGate, L.C. is actively commercializing products pursuant to the Sublicense Agreement. SmartGate, L.C. is in full compliance with said Agreement, and to the best of its knowledge, RadioMetrix is in full compliance with said Agreement. As a result of the commercialization of products and the development of technology pursuant to the Sublicense Agreement, SmartGate, through its Independent Committee of Directors, has determined that it is in SmartGate's best interest to expand its rights, interests, and ownership of the RadioMetrix Technology.
Sublicense Agreement. Anthera shall provide Lilly with a copy of each sublicense under the license rights granted to Anthera in Section 2.1 that it enters into, whether entered into in accordance with Section 2.3(a) or 2.3(b) hereof, promptly following the execution thereof by the parties thereto.
Sublicense Agreement. Concurrent with the execution and delivery of this Amendment, Kadmon and AbbVie shall enter into the sublicense agreement, attached hereto as Exhibit A (the “Sublicense Agreement”), under that certain License Agreement by and between Merck CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION & Sharp & Dohme Corp. (successor to Schering Corporation) and Kadmon Pharmaceuticals, LLC (successor to Three Rivers Pharmaceuticals, LLC), dated February 7, 2003, as amended by the First Amendment to License Agreement, dated October 28, 2013.